Which patients with cSCC could you omit adjuvant radiation following pathologic complete response following cemiplimab?  

I think we need to distinguish between pCR as assessed by a random biopsy versus a complete resection of the involved primary site - the latter is rarely performed since the premise for giving cemiplimab in the first place would have been to avoid a morbid surgery. pCR is not always easy to assess f...

The true answer is that we do not know. In the published NEJM paper, by Neil Gross et al. the primary objective was pathologic response. Given the excellent overall pathological responses achieved with neoadjuvant cemiplimab, many of us in the head and neck community believe that this is a reasonabl...